When Valeant Pharmaceuticals International Inc. (NYSE: VRX) and activist investor Bill Ackman made an unsolicited $46 billion bid to purchase Botox maker Allergan Inc. (NYSE: AGN) last week, investors ...

Actavis said it would pay $66 billion in cash and stock for in a deal that appears to have thwarted a hostile takeover of the Botox maker. David Benoit joins MoneyBeat. Photo: AP. Two years ago, ...

On Wednesday, AEON Biopharma, Inc. (NYSE: AEON) stock received continued support from H.C. Wainwright, with the investment firm maintaining a Buy rating and a $6.00 price target. AEON Biopharma ...

Allergan PLC agreed to buy Kythera Biopharmaceuticals Inc. and its newly approved double-chin treatment in a $2.1 billion deal Wednesday that aims to plump up the Botox maker’s lineup of cosmetic ...